Mostrar el registro sencillo del ítem

dc.contributor.authorRivero Calle, Irene 
dc.contributor.authorRaguindin, P.F.
dc.contributor.authorPardo Seco, Jacobo José
dc.contributor.authorMartinón Torres, Federico 
dc.date.accessioned2025-08-25T12:40:19Z
dc.date.available2025-08-25T12:40:19Z
dc.date.issued2022
dc.identifier.citationRivero-Calle I, Raguindin PF, Pardo-Seco J, Martinon-Torres F. Risk Analysis by Age on the Burden of Meningococcal Disease in Spain. Vaccines. 2022;10(4).
dc.identifier.issn2076-393X
dc.identifier.otherhttps://portalcientifico.sergas.gal/documentos/628009ae3333e458234bb83c*
dc.identifier.urihttp://hdl.handle.net/20.500.11940/20495
dc.description.abstractWe conducted an age-based risk analysis of meningococcal disease in Spain to provide prospects on a rational vaccine schedule in pediatrics. We used the National Hospital Registry to estimate meningococcal hospitalization rate. Population census for each year was used as the denominator in computing the hospitalization rate. We computed the odds ratio of each age using <1 year old as a reference group. From 1998 to 2017, 13,554 hospitalized cases were diagnosed, with a declining trend across the years. Infants (<1 year, n = 2425) and children (1-14 years, n = 6053) comprised the majority of all hospitalized meningococcal disease in Spain (62.5% or 8474/13,554). The incidence of hospitalization decreased dramatically with age from 56.2/100,000 in <1-year-old children to 1.3/100,000 in >5-year-old children. There was a dramatic decline in risk in 1 year (OR 0.58) to 4 years of age (OR 0.21). The risk continued to decline until 13 years old. Afterward, it had a minimal upward trajectory observed at 14-17 years old (OR 0.08). Infants and adolescents are at continued risk of invasive meningococcal disease in Spain. The highest risk occurs in infants. Surveillance data, together with evidence on long-term immunogenicity and capacity for herd effect, should be considered for a more relevant immunization schedule.en
dc.description.sponsorshipThis study received support from the Instituto de Salud Carlos III through projects ReSVinext (Instituto de Salud Carlos III(ISCIII)/PI16/01569/Cofinanciado FEDER), and Enterogen (Instituto de Salud Carlos III(ISCIII)/PI19/01090/Cofinanciado FEDER) given to F.M.T.en
dc.language.isoeng
dc.rightsAtribución 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.titleRisk Analysis by Age on the Burden of Meningococcal Disease in Spain*
dc.typeArticleen
dc.authorsophosRivero-Calle, F. I.
dc.authorsophosRaguindin, P. F.
dc.authorsophosPardo-Seco, J.
dc.authorsophosMartinon, Torres
dc.identifier.doi10.3390/vaccines10040592
dc.identifier.sophos628009ae3333e458234bb83c
dc.issue.number4
dc.journal.titleVaccines*
dc.page.initialnull
dc.relation.projectIDInstituto de Salud Carlos III [PI16/01569, PI19/01090]; FEDER
dc.relation.publisherversionhttps://boris.unibe.ch/169428/1/Rivero-Calle_Vaccines_2022.pdf;https://mdpi-res.com/d_attachment/vaccines/vaccines-10-00592/article_deploy/vaccines-10-00592-v2.pdf?version=1649904322es
dc.rights.accessRightsopenAccess
dc.subject.keywordAS Santiagoes
dc.subject.keywordCHUSes
dc.subject.keywordIDISes
dc.typefidesArtículo Científico (incluye Original, Original breve, Revisión Sistemática y Meta-análisis)es
dc.typesophosArtículo Originales
dc.volume.number10


Ficheros en el ítem

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución 4.0 Internacional
Excepto si se señala otra cosa, la licencia del ítem se describe como Atribución 4.0 Internacional